Investigational drug · Phase 2
Sequential Epirubicin
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Breast Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Mar 19, 2024 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
42
Any phase or sponsor naming "Sequential Epirubicin"
First trial start
2023
Jul 27, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Sequential Epirubicin", any sponsor or status.
Conditions studied
As listed on its trial records.
- Breast Cancer
Approved drugs for the same conditions: Breast cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Sequential Epirubicin" as an intervention, largest first.
- Anthracycline-free Taxane Based Chemotherapy in Patients With HER2/Neu Negative Early Breast CancerPivotal-lookingCompleted
Women's Cancer Study Group GmbHAcademic, hospital or other
NCT01049425 · 3,198 participants · Start Feb 5, 2009 · Primary completion Mar 1, 2017
Drug: Epirubicin; Cyclophosphamide and 3 more · For: Primary Breast Cancer; Her2 Non-overexpressing
Sites: Mönchengladbach, Germany
- Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast CancerPivotal-lookingCompleted
UNICANCERAcademic, hospital or other
NCT00054587 · 3,010 participants · Start Jun 2001 · Primary completion Jun 2009
Drug: Trastuzumab; Cyclophosphamide and 3 more · For: Breast Cancer
Sites: Angers, France; Annecy, France; Bordeaux, France · 29 sites in all
- 4 x Epirubicin, Cyclophosphamide, Followed by 4 x Docetaxel Versus 6 x CMF / 6 x CEFPivotal-lookingCompleted
Women's Cancer Study Group GmbHAcademic, hospital or other
NCT02115204 · 2,011 participants · Start Jun 2000 · Primary completion Aug 2005
Drug: Epirubicin; Cyclophosphamide and 3 more · For: Breast Cancer
Sites: Mönchengladbach, Germany
- Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast CancerPivotal-lookingCompleted
Spanish Breast Cancer Research GroupAcademic, hospital or other
NCT00129922 · 1,289 participants · Start Nov 1999 · Primary completion Dec 2005
Drug: paclitaxel; Fluorouracil and 2 more · For: Breast Cancer
Sites: Alcoy, Spain; Elche, Spain; Elda, Spain · 64 sites in all
- Combination Chemotherapy Following Surgery in Treating Women With Early Stage Breast CancerPivotal-lookingCompleted
Scottish Cancer Therapy NetworkAcademic, hospital or other
NCT00003012 · 1,000 participants (planned) · Start Oct 1996
Drug: CMF regimen; cyclophosphamide and 3 more · For: Breast Cancer
Sites: Leicester, United Kingdom; Aberdeen, United Kingdom; Dundee, United Kingdom · 10 sites in all
- Study of Docetaxel in Breast Cancer PatientsPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT00174707 · 998 participants · Start Dec 1997 · Primary completion Dec 2007
Drug: epidoxorubicine, ciclophosphamide, methotrexate, fluorouracile; epidoxorubicine, docetaxel, ciclophosphamide, methotrexate, fluorouracile and 1 more · For: Breast Neoplasms
Sites: Milan, Italy
- Neoadjuvant Epirubicin, Cyclophosphamide, and Paclitaxel With or Without Gemcitabine in Treating Women Who Are Undergoing Surgery for Early Breast CancerPivotal-lookingStatus unknown
Cambridge University Hospitals NHS Foundation TrustAcademic, hospital or other
NCT00070278 · 800 participants (planned) · Start Jan 2005 · Primary completion Sep 2007
Drug: cyclophosphamide; epirubicin hydrochloride and 2 more · For: Breast Cancer
Sites: Cambridge, United Kingdom
- Studying the Benefits of Adjuvant Sequential vs. Combined Taxane Based Chemotherapy, Followed by Different Biological Treatment Strategies in Early, HER2-positive Breast CancerPivotal-lookingCompleted
Ludwig-Maximilians - University of MunichAcademic, hospital or other
NCT00670878 · 799 participants (planned) · Start Jun 2008 · Primary completion Oct 2011
Drug: 3 x FEC 3 x DOC / Gemcitabine; 3 x FEC 3 x DOC · For: Breast Cancer
Sites: Munich, Germany
- Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast CancerPivotal-lookingCompleted
UNICANCERAcademic, hospital or other
NCT00630032 · 762 participants · Start Sep 2007 · Primary completion Jun 2017
Drug: cyclophosphamide; Docetaxel and 3 more · For: Breast Cancer
Sites: Scottsdale, Arizona; Denver, Colorado; Jacksonville, Florida · 86 sites in all
- Preoperative Epirubicin Paclitaxel Aranesp Study (PREPARE)Pivotal-lookingCompleted
GBG Forschungs GmbHAcademic, hospital or other
NCT00544232 · 720 participants · Start Aug 2002 · Primary completion Sep 2006
Drug: Epirubicin, paclitaxel, cyclophosphamide, Methotrexate, 5 FU, darbepoetin alfa; Epirubicin, Cyclophosphamide, Paclitaxel, dabepoetin alfa · For: Breast Cancer
Newest research
PubMed records naming it or its code names, newest first.
- The impact of functional MDM2-polymorphisms on neutrophil counts in breast cancer patients during neoadjuvant chemotherapy.
Hatletvedt ND, Engebrethsen C, Geisler J, et al. · BMC Cancer 2025
- Benefit from dose-dense adjuvant chemotherapy for breast cancer: subgroup analyses from the randomised phase 3 PANTHER trial.
Matikas A, Papakonstantinou A, Loibl S, et al. · Lancet Reg Health Eur 2025
- Tailored Dose-Dense Versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer: End-of-Study Results of the Randomized PANTHER Trial.
Matikas A, Möbus V, Greil R, et al. · J Clin Oncol 2024
- Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy.
Venizelos A, Engebrethsen C, Deng W, et al. · Genome Med 2022
- The impact of progesterone receptor expression on prognosis of patients with rapidly proliferating, hormone receptor-positive early breast cancer: a post hoc analysis of the IBIS 3 trial.
Bravaccini S, Bronte G, Scarpi E, et al. · Ther Adv Med Oncol 2020
- Evaluating the role of magnetic resonance imaging post-neoadjuvant therapy for breast cancer in the NEONAB trial.
Murphy C, Mukaro V, Tobler R, et al. · Intern Med J 2018
Also in development for Breast Cancer
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- SHR-A1811Trastuzumab RezetecanPhase 327 trials
Jiangsu HengRui Medicine Co., Ltd. · Advanced Colorectal Cancer, Recurrent or Metastatic Cervical Cancer, Ovarian Cancer
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- GiredestrantRO7197597, GDC-9545Phase 316 trials
Roche (Genentech) · Early Breast Cancer, Breast Cancer, Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
- TQB2102Phase 311 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Breast Cancer, HER2-positive Breast Cancer, Gynecological Tumors
- SaruparibAZD5305Phase 310 trials
AstraZeneca · Prostate Cancer, Ovarian Cancer, Endometrial Cancer
- AtirmociclibPF-07220060Phase 39 trials
Pfizer · Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer
- RC148Phase 38 trials
RemeGen Co., Ltd. · Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations, Solid Tumor, Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.